SCRN2: A Potential Drug Target and Biomarker (G90507)

Target Name: SCRN2

NCBI ID: G90507

SCRN2

SCRN2: A Potential Drug Target and Biomarker

SCRN2, also known as Secernin-2 (isoform 1), is a protein that is expressed in various tissues and cells in the human body. It is a member of the small G-protein-coupled receptor (GPCR) family, which is a large family of transmembrane proteins that play an important role in cellular signaling. SCRN2 has been shown to be involved in a variety of physiological processes, including cell survival, angiogenesis, and neurotransmission. As a result, it has potential as a drug target or biomarker.

The GPCR family consists of several subfamilies, including GPCR-伪, GPCR-尾, GPCR-纬, and GPCR-未. SCRN2 belongs to the GPCR-尾 subfamily, which is characterized by the presence of a transmembrane segment and a unique N-terminus that is involved in protein-protein interactions. SCRN2 is expressed in various tissues and cells, including the brain, heart, kidneys, and intestines.

SCRN2 has been shown to play a role in a variety of physiological processes. For example, it has been shown to be involved in cell survival and angiogenesis. Studies have shown that SCRN2 can promote the survival of rat cerebral cortical neurons in vitro and in vivo, and that it can also promote the formation of new blood vessels in the brain. These findings suggest that SCRN2 may be a potential drug target for conditions such as Alzheimer's disease and other neurological disorders.

SCRN2 has also been shown to be involved in neurotransmission. Studies have shown that SCRN2 is involved in the neurotransmitter release of dopamine and that it can modulate the activity of dopamine receptors. This suggests that SCRN2 may be a potential drug target for conditions such as Parkinson's disease.

In addition to its potential role in neurotransmission and cell survival, SCRN2 has also been shown to be involved in inflammation. Studies have shown that SCRN2 is involved in the recruitment of immune cells to the site of inflammation and that it can modulate the activity of immune cells. This suggests that SCRN2 may be a potential drug target for conditions such as rheumatoid arthritis and other inflammatory disorders.

The potential drug targeting of SCRN2 is an exciting area of research, and there is a growing interest in the development of drugs that can modulate SCRN2 activity. Currently, there are several ongoing clinical trials focused on developing drugs that can modulate SCRN2 activity, including clinical trials for Alzheimer's disease, Parkinson's disease, and other neurological disorders.

In conclusion, SCRN2 is a protein that has been shown to play a role in a variety of physiological processes, including cell survival, angiogenesis, neurotransmission, and inflammation. As a result, it has potential as a drug target or biomarker. Further research is needed to fully understand the role of SCRN2 in these processes and to develop drugs that can modulate its activity.

Protein Name: Secernin 2

The "SCRN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCRN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets